



Contents lists available at ScienceDirect

Asian Pacific Journal of Tropical Disease

journal homepage: www.elsevier.com/locate/apjtd



Microbiological research doi: 10.1016/S2222-1808(16)61135-0 ©2016 by the Asian Pacific Journal of Tropical Disease. All rights reserved.

Antibacterial effect of silver nanoparticles and capsaicin against MDR-ESBL producing *Escherichia coli*: An *in vitro* studyDebashish Kar¹, Samiran Bandyopadhyay^{2*}, Umesh Dimri¹, Deba Brata Mondal¹, Pramod Kumar Nanda², Arun Kumar Das², Subhasish Batabyal³, Premanshu Dandapat², Subhasish Bandyopadhyay²¹Indian Council of Agricultural Research, Indian Veterinary Research-Institute, Izatnagar 243 122, Bareilly, Uttar Pradesh, India²Eastern Regional Station, Indian Council of Agricultural Research-Indian Veterinary Research Institute, 37 Belgachia Road, Kolkata 700 037, West Bengal, India³West Bengal University of Animal and Fishery Sciences, 37 & 68 Kshudiram Bose Sarani, Kolkata 700 037, West Bengal, India

ARTICLE INFO

Article history:

Received 13 Apr 2016

Received in revised form 17 May 2016

Accepted 5 Jul 2016

Available online 17 Aug 2016

Keywords:

Silver nanoparticles

Capsaicin

Extended-spectrum beta-lactamase

Escherichia coli

ABSTRACT

Objective: To evaluate the antibacterial property of silver nanoparticles (AgNPs) and capsaicin against multidrug resistant (MDR) and extended spectrum beta-lactamase (ESBL) producing *Escherichia coli* of bovine and poultry origin.**Methods:** Antibacterial efficacy of AgNPs and capsaicin was measured using broth dilution method. Five MDR-ESBL producing *E. coli* isolates of poultry (PEC4, PEC6, PEC15 and PEC16) and cattle mastitis origin (MEC2) were taken to evaluate the antibacterial effect of AgNPs and capsaicin.**Results:** At 50 mmol/L AgNPs, the viability of MDR of bacterial pathogens was reduced to almost 80%–90% and at 1000 mmol/L, the viability went down to 0%–3%. The minimum inhibitory concentration (MIC₅₀) of AgNPs against these MDR-ESBL producing isolates was found to vary between 172–218 mmol/L whereas the MIC₈₀ varied between 450–640 mmol/L. Capsaicin showed more prominent bactericidal effect and only at 2.5 mmol/L concentration, the viability was shown to be reduced by 20%–35% whereas at 7.5 mmol/L concentration, there was approximately 60% reduction in viability. Further at 25 mmol/L concentration, the viability was reduced to 0%–8%. The MIC₅₀ and MIC₈₀ of capsaicin against these MDR-ESBL producing isolates were found to vary between 4.6–7.5 mmol/L and 10.9–16.9 mmol/L, respectively.**Conclusions:** The results point out that capsaicin and AgNPs could be of use in treating ESBL infection.

1. Introduction

Indiscriminate and inadvertent use of antibiotics has been often regarded as the main cause behind the rising problem of antimicrobial resistance worldwide leading to emergence of multidrug resistant (MDR) pathogens. Amongst the MDR pathogens, extended spectrum beta-lactamase (ESBL) producing *Escherichia coli* (*E. coli*) is often responsible for therapeutic failure and poor infection control programme leading to increased mortality and morbidity in human. This is due to its ability to inactivate β-lactam

antibiotics including newer generation of oxyimino-cephalosporin (cefepodoxime, ceftazidime, ceftriaxone and cefotaxime) and oxyimino-monobactam (aztreonam). Although these pathogens were more commonly known for hospital-acquired infections, recent reports suggest its wide scale involvement in community borne infection as well[1]. As most of the ESBL producers are MDR and cannot be easily treated, it has become a real cause of concern for public health[2]. Furthermore, indiscriminate use of antibiotics in livestock sector often results in emergence of several antibiotic resistant strains, including ESBL producers in animals. In such cases, the animals not only act as a mere reservoir, but may in turn transmit these pathogens to human beings through direct and indirect contact[3]. The occurrence of ESBL producing MDR-*E. coli* in food-producing animals has recently been reported by this group of authors from India[4].

The emergence of MDR pathogenic organisms in human and animals has become a major cause of therapeutic failure of

*Corresponding author: Samiran Bandyopadhyay, Eastern Regional Station, Indian Council of Agricultural Research, Indian Veterinary Research Institute, 37 Belgachia Road, Kolkata 700037, West Bengal, India.

Tel: +91 9434082634

Fax: +91 3325565725

E-mail: samiranvet@gmail.com, samiran.b@icar.gov.in

The journal implements double-blind peer review practiced by specially invited international editorial board members.

infectious diseases[5]. Although several new antibiotics have been developed in the last few decades, none of them offer improved activity against MDR bacteria[6]. This coupled with diminishing therapeutic values of different frontier antimicrobials has renewed the interest of researchers to search for some novel alternatives and to look for new antimicrobial substances.

Nanoparticles with one dimension of 100 nm or less in size are now being increasingly utilised for medical applications and are of great interest as an alternative approach to control infectious agents offering broad spectrum activities against bacteria, fungi and viruses[7]. Recent studies have shown that metal-based nanoparticles are one of the most promising therapeutic agents owing to their unique physico-chemical and biological properties[8]. Besides, the search for plant secondary metabolites including phytochemicals and extracts derived from plants has accelerated in recent years and their use can be an interesting alternative to control bacterial infections[9]. One such secondary plant metabolite is capsaicin, which is known for its multiple pharmacological and physiological properties and has recently attracted considerable attention because of its antimicrobial and anti-virulence activity[10,11].

In view of the importance of MDR pathogens and the quest to search for suitable and alternative approach to control them, the present study was conducted to evaluate the antibacterial effect of silver nanoparticles (AgNPs) and a plant-derived compound-capsaicin against few MDR-ESBL producing *E. coli* isolates of bovine and poultry origin.

2. Materials and methods

2.1. Bacterial isolates

Five MDR-ESBL producing *E. coli* isolates of poultry (PEC4, PEC6, PEC15 and PEC16) and cattle mastitis origin (MEC2) were taken to evaluate the antibacterial effect of AgNPs and capsaicin. In general, organisms that were resistant to three or more classes of antibiotics were considered as MDR. In this study, these isolates were resistant to at least six antibiotics belonging to diverse groups.

2.2. AgNPs

AgNPs of 100 nm size with 107.87 molecular weight, 0.9987 g/mL density and 0.02 mg/mL concentration were procured from Sigma-Aldrich, USA.

2.3. Capsaicin

Capsaicin [8-methyl-N-Vanillyl-trans-6-nonenamide ($C_{18}H_{27}NO_3$) of 305.41 molecular weight] was procured from HiMedia, India in powder form and the stock solution (1 mol/L) was prepared as per the manufacturer's instructions.

2.4. Determination of minimum inhibitory concentration (MIC_{50} and MIC_{80}) of AgNPs and capsaicin

The minimum inhibitory concentrations (MIC_{50} and MIC_{80}) of AgNPs and capsaicin were determined against the MDR-ESBL producing *E. coli* isolates using the broth dilution method as described previously[9]. Briefly, sterile test tubes containing

10 mL of nutrient broth were supplemented with various concentrations of AgNPs (0, 6.25, 12.5, 25, 50, 100, 250, 500 and 1000 mmol/L) and capsaicin (0, 2.5, 5.0, 7.5, 12.5 and 25 mmol/L). Thereafter, the tubes were inoculated with each MDR-ESBL producing strains (1.5×10^6 to 3×10^6 /mL) and incubated at 37 °C for 24 h. The optical density at 650 nm (OD_{650}) of the tubes was recorded at 0 h (beginning of lag phase) and once again after 24 h of incubation at 37 °C. The viability of the organism was calculated in terms of turbidity and the difference between final and initial OD_{650} . Specific OD_{650} was interpreted as the growth of the bacteria. The percent viability of bacteria at any specific concentration was calculated as per the following formula:

Percent viability = $\left\{ \frac{[\text{Specific } OD_{650} (\text{Final } OD_{650} - \text{Initial } OD_{650}) \text{ for any concentration of AgNPs or capsaicin}]}{[\text{Specific } OD_{650} (\text{Final } OD_{650} - \text{Initial } OD_{650}) \text{ of negative control}]} \right\} \times 100$. Further, the MIC_{50} and MIC_{80} were calculated for both AgNPs and capsaicin using Graphpad prism software version 5.0.

3. Results

The antibacterial activity of AgNPs against five ESBL producing MDR-*E. coli* isolates was determined by broth dilution assay using AgNPs at concentrations varying from 0 to 1000 mmol/L (0.00, 6.25, 12.5, 25, 50, 100, 500 and 1000 mmol/L) and was presented in Figure 1. The bacterial viability was reduced to 80%–90% using AgNPs at 50 mmol/L concentration, whereas at 100 mmol/L concentration, there was approximately 40% reduction in viability. The bacterial viability was reduced to 0%–3% only at 1000 mmol/L. The MIC_{50} of AgNPs against these MDR-ESBL isolates was found to vary between 172–218 mmol/L, whereas the MIC_{80} varied between 450–640 mmol/L.




Figure 1. Antibacterial effect of AgNPs towards ESBL producing *E. coli*.

Likewise, the antibacterial effect of capsaicin determined by broth dilution assay was also tested against the isolates of ESBL producers at concentrations ranging from 0 to 25 mmol/L (Figure 2). At 2.5 mmol/L concentration, the bacterial viability was found to be reduced by 20%–35%, whereas at 7.5 mmol/L concentration, there was approximately 60% reduction in viability. At 25 mmol/L concentration, the viability was reduced to 0%–8%. The MIC_{50} of capsaicin against these MDR-ESBL producing isolates was found to be 4.6–7.5 mmol/L. The MIC_{80} was also detected to vary between 10.9–16.9 mmol/L.




Figure 2. Antibacterial effect of capsaisin towards ESBL producing *E. coli*.

4. Discussion

Nowadays, antimicrobial resistance is a serious concern in hospitals, public healthcare systems and veterinary practices as well worldwide. In livestock sector, emergence of antimicrobial resistance not only complicates the therapeutic options and clinical outcome of important animal diseases but also has a huge impact over farming economy. To overcome this burgeoning problem, scientific efforts are on in pursuit of alternative therapeutics to tackle these MDR strains.

In recent years, researchers have witnessed metal-based nanoparticles as an effective alternative for disease control. Studies have also shown that metal nanoparticles, in particular silver ions exert strong inhibitory and bactericidal effects as well as possess a broad spectrum of antimicrobial activities[12,13]. Various modes of action for antibacterial effects of AgNPs are because of the change of bacterial cell membrane permeability and interaction of AgNPs with sulfhydryl group of essential enzymes thereby facilitating release of K^+ ion from bacterial cells[14,15].

In the present study, AgNPs used were spherical with a particle size of 100 nm. MIC_{50} and MIC_{80} of AgNPs for the tested MDR isolates of *E. coli* ranged from 172 to 218 mmol/L and 450 to 640 mmol/L, respectively. The antimicrobial effect of AgNPs and its activity against the MDR pathogens have been evaluated by various researchers. In a study, Amirulhusni *et al.* recorded MIC_{50} at a concentration of 15 μ g/mL and reported total inhibition potential of AgNPs (≥ 50 μ g/mL concentration) against MDR strain of *Pseudomonas aeruginosa* (*P. aeruginosa*)[16]. Lara *et al.* determined the antibacterial effect and found concentrations of AgNPs between 30 and 100 mmol/L effective against various resistant and drug susceptible bacterial strains[17]. Paredes *et al.* evaluated the antibacterial effect of AgNPs against MDR-*E. coli* and recorded MIC value at 25 μ g/mL[18]. AgNPs were also found effective against ESBL producing bacteria at 100 mg/mL concentration[19]. Further, green AgNPs synthesized by *Streptomyces* sp. (VITSJK10) were found to have significant antimicrobial activity against MDR-ESBL pathogens like *Klebsiella pneumoniae*, *E. coli*, *etc.*[20]. Few researchers have also compared antibacterial activity of AgNPs against MDR bacterial pathogens employing agar well diffusion and turbidometric assays[21,22].

As a wide variety of methods are employed to study the antibacterial effect of AgNPs by various researchers, it makes the comparison of results to be a difficult task. Nevertheless, the variation in size, shape, stability and concentration could also have influenced

the efficacy of AgNPs against microorganisms. In fact, particle size plays a central role in antimicrobial activity, as small particles exhibit higher antimicrobial activity than the big particles[23]. Again, shape of the AgNPs also determines the antibacterial effectivity of AgNPs and displays a shape-dependent interaction with the bacterial cells. Previous studies indicated that truncated triangular AgNPs display the strongest biocidal action against *E. coli* as compared to spherical and rod-shaped nanoparticles[24,25]. So, *in vivo* studies to define a safe range for the application of AgNPs are required.

Since long, chile peppers are known to show antimicrobial property[26]. Capsaicin, the secondary plant metabolite used in this study is an active component and pungent ingredient found in a variety of peppers of the genus *Capsicum*[27]. Reports suggest that capsaicin is effective against a number of ailments including respiratory problems, and even displays inhibitory potential against foodborne pathogens like *Salmonella typhimurium* and *P. aeruginosa*[28].

In the present study, capsaisin was also found to have an appreciable antibacterial effect against ESBL producing MDR *E. coli* isolates with the MIC_{50} and MIC_{80} ranging between 4.6–7.5 mmol/L and 10.9–16.9 mmol/L, respectively. Capsaicin was previously reported to mediate antibacterial effect by changing the membrane fluidity and efflux pump inhibition against NorA thereby conferring resistance on *Staphylococcus aureus* to norfloxacin[29,30]. *In vitro* bactericidal activity of capsaisin against *Helicobacter pylori* has also been documented at 50 μ g/mL[31]. Further, the antibacterial effect of this flavonoid was also reported against *Vibrio cholera*, *Salmonella typhimurium*, *P. aeruginosa* and *Bacillus subtilis* in the recent past[28,32,33].

Although several studies have demonstrated that capsaisin possesses antimicrobial activity against various MDR Gram-positive and Gram-negative bacteria, none of them reported the effects of capsaisin against MDR *E. coli* to substantiate the findings of this study[34,35]. However, before its clinical trial, the carcinogenic potential of capsaisin should be investigated thoroughly, as it modulates xenobiotic metabolizing enzymes, particularly microsomal cytochrome P450-dependent monooxygenases, which are involved in activation of various chemical carcinogens and mutagens[36,37].

In conclusion, AgNPs and capsaisin could effectively be used and act as tool to inhibit the growth of MDR-ESBL producing *E. coli* pathogen. However, to explore more possible uses of AgNPs and capsaisin as antimicrobial agents, research involving *in vivo* study with combination therapy is suggested which may help to reduce the MDR burden and prevent its further transmission into different clinical environments.

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgments

The authors wish to acknowledge the Director, Indian Council of Agricultural Research, Indian Veterinary Research Institute, Izatnagar, Uttar Pradesh, Bareilly, India, for providing necessary facilities to carry out the research work.

References

- [1] Kassakian SZ, Mermel LA. Changing epidemiology of infections due to extended spectrum beta-lactamase producing bacteria. *Antimicrob Resist Infect Control* 2014; 3: 9.

- [2] Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. *Int J Med Microbiol* 2010; **300**: 371-9.
- [3] Timofte D, Maciucu IE, Evans NJ, Williams H, Wattret A, Fick JC, et al. Detection and molecular characterization of *Escherichia coli* CTX-M-15 and *Klebsiella pneumoniae* SHV-12 β -lactamases from bovine mastitis isolates in the United Kingdom. *Antimicrob Agents Chemother* 2014; **58**: 789-94.
- [4] Kar D, Bandyopadhyay S, Bhattacharyya D, Samanta I, Mahanti A, Nanda PK, et al. Molecular and phylogenetic characterization of multidrug resistant extended spectrum beta-lactamase producing *Escherichia coli* isolated from poultry and cattle in Odisha, India. *Infect Genet Evol* 2015; **29**: 82-90.
- [5] Ibrahim TA, Opawale BO, Oyinloye JMA. Antibacterial activity of herbal extracts against multi drug resistant strains of bacteria from clinical origin. *Life Sci Leaflets* 2011; **15**: 490-8.
- [6] Mohanty S, Mishra S, Jena P, Jacob B, Sarkar B, Sonawane A. An investigation on the antibacterial, cytotoxic, and antibiofilm efficacy of starch-stabilized silver nanoparticles. *Nanomedicine* 2012; **8**(6): 916-24.
- [7] Seil JT, Webster TJ. Antimicrobial applications of nanotechnology: methods and literature. *Int J Nanomedicine* 2012; **7**: 2767-81.
- [8] Franci G, Falanga A, Galdiero S, Palomba L, Rai M, Morelli G, et al. Silver nanoparticles as potential antibacterial agents. *Molecules* 2015; **20**: 8856-74.
- [9] Bandyopadhyay S, Patra PH, Mahanti A, Mondal DK, Dandapat P, Bandyopadhyay S, et al. Potential antibacterial activity of berberine against multi drug resistant enterovirulent *Escherichia coli* isolated from yaks (*Poephagus grunniens*) with haemorrhagic diarrhoea. *Asian Pac J Trop Med* 2013; **6**: 315-9.
- [10] Nascimento PL, Nascimento TC, Ramos NS, Silva GR, Gomes JE, Falcão RE, et al. Quantification, antioxidant and antimicrobial activity of phenolics isolated from different extracts of *Capsicum frutescens* (*Pimenta malagueta*). *Molecules* 2014; **19**: 5434-47.
- [11] Marini E, Magi G, Mingoia M, Pugnali A, Facinelli B. Antimicrobial and anti-virulence activity of capsaicin against erythromycin-resistant, cell-invasive Group A *Streptococci*. *Front Microbiol* 2015; **6**: 1281.
- [12] Kim JS, Kuk E, Yu KN, Kim JH, Park SJ, Lee HJ, et al. Antimicrobial effects of silver nanoparticles. *Nanomedicine* 2007; **3**: 95-101.
- [13] Swain P, Nayak SK, Sasmal A, Behera T, Barik SK, Swain SK, et al. Antimicrobial activity of metal based nanoparticles against microbes associated with diseases in aquaculture. *World J Microbiol Biotechnol* 2014; **30**: 2491-502.
- [14] Krishnaraj C, Jagan EG, Rajasekar S, Selvakumar P, Kalaichelvan PT, Mohan N. Synthesis of silver nanoparticles using *Acalypha indica* leaf extracts and its antibacterial activity against water borne pathogens. *Colloids Surf B Biointerfaces* 2010; **76**: 50-6.
- [15] Ivask A, Elbadawy A, Kaweeteerawat C, Boren D, Fischer H, Ji Z, et al. Toxicity mechanisms in *Escherichia coli* vary for silver nanoparticles and differ from ionic silver. *ACS Nano* 2014; **8**: 374-86.
- [16] Amirulhusni AN, Palanisamy NK, Mohd-Zain Z, Ping LJ, Durairaj R. Antibacterial effect of silver nanoparticles on multi drug resistant *Pseudomonas aeruginosa*. *Int J Med Health Biomed Bioeng Pharm Eng* 2012; **6**(7): 291-4.
- [17] Lara HH, Ayala-Núñez NV, del Carmen Ixtepan Turrent L, Padilla CR. Bactericidal effect of silver nanoparticles against multidrug-resistant bacteria. *World J Microbiol Biotechnol* 2010; **26**: 615-21.
- [18] Paredes D, Ortiz C, Torres R. Synthesis, characterization, and evaluation of antibacterial effect of Ag nanoparticles against *Escherichia coli* O157: H7 and methicillin-resistant *Staphylococcus aureus* (MRSA). *Int J Nanomedicine* 2014; **9**: 1717-29.
- [19] Doudi M, Naghsh N, Setorki M. Comparison of the effects of silver nanoparticles on pathogenic bacteria resistant to beta-lactam antibiotics (ESBLs) as a prokaryote model and Wistar rats as a eukaryote model. *Med Sci Monit Basic Res* 2013; **19**: 103-10.
- [20] Subashini J, Khanna VG, Kannabiran K. Anti-ESBL activity of silver nanoparticles biosynthesized using soil *Streptomyces* species. *Bioprocess Biosyst Eng* 2014; **37**: 999-1006.
- [21] Gopinath PM, Narchonai G, Dhanasekaran D, Ranjani A, Thajuddin N. Mycosynthesis, characterization and antibacterial properties of AgNPs against multidrug resistant (MDR) bacterial pathogens of female infertility cases. *Asian J Pharm Sci* 2015; **10**: 138-45.
- [22] Cavassin ED, de Figueiredo LF, Otoch JP, Seckler MM, de Oliveira RA, Franco FF, et al. Comparison of methods to detect the *in vitro* activity of silver nanoparticles (AgNP) against multidrug resistant bacteria. *J Nanobiotechnology* 2015; **13**: 64.
- [23] Rai MK, Deshmukh SD, Ingle AP, Gade AK. Silver nanoparticles: the powerful nanoweapon against multidrug-resistant bacteria. *J Appl Microbiol* 2012; **112**: 841-52.
- [24] Pal S, Tak YK, Song JM. Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the Gram-negative bacterium *Escherichia coli*. *Appl Environ Microbiol* 2007; **73**: 1712-20.
- [25] Sharma VK, Yngard RA, Lin Y. Silver nanoparticles: green synthesis and their antimicrobial activities. *Adv Colloid Interface Sci* 2009; **145**: 83-96.
- [26] Omolo MA, Wong ZZ, Mergen AK, Hastings JC, Le NC, Reiland HA, et al. Antimicrobial properties of chili peppers. *J Infect Dis Ther* 2014; **2**: 145.
- [27] Reyes-Escogido Mde L, Gonzalez-Mondragon EG, Vazquez-Tzompantzi E. Chemical and pharmacological aspects of capsaicin. *Molecules* 2011; **16**: 1253-70.
- [28] Careaga M, Fernández E, Dorantes L, Mota L, Jaramillo ME, Hernandez-Sanchez H. Antibacterial activity of *Capsicum* extract against *Salmonella typhimurium* and *Pseudomonas aeruginosa* inoculated in raw beef meat. *Int J Food Microbiol* 2003; **83**: 331-5.
- [29] Tsuchiya H. Membrane interactions of phytochemicals as their molecular mechanism applicable to the discovery of drug leads from plants. *Molecules* 2015; **20**: 18923-66.
- [30] Kalia NP, Mahajan P, Mehra R, Nargotra A, Sharma JP, Koul S, et al. Capsaicin, a novel inhibitor of the NorA efflux pump, reduces the intracellular invasion of *Staphylococcus aureus*. *J Antimicrob Chemother* 2012; **67**(10): 2401-8.
- [31] Zeyrek FY, Oguz E. *In vitro* activity of capsaicin against *Helicobacter pylori*. *Ann Microbiol* 2005; **55**: 125-7.
- [32] Yamasaki S, Asakura M, Neogi SB, Hinenoya A, Iwaoka E, Aoki S. Inhibition of virulence potential of *Vibrio cholerae* by natural compounds. *Indian J Med Res* 2011; **133**: 232-9.
- [33] Stephen BJ, Kumar V. Evaluation of antimicrobial activity of capsaicin extract against *B. subtilis* species. *Int J Pharm Drug Anal* 2014; **2**: 111-6.
- [34] Santos MM, Vieira-da-Motta O, Vieira IJ, Braz-Filho R, Gonçalves PS, Maria EJ, et al. Antibacterial activity of *Capsicum annum* extract and synthetic capsaicinoid derivatives against *Streptococcus mutans*. *J Nat Med* 2012; **66**(2): 354-6.
- [35] Noumedem JA, Mihasan M, Lacmata ST, Stefan M, Kuate JR, Kuete V. Antibacterial activities of the methanol extracts of ten Cameroonian vegetables against Gram-negative multidrug-resistant bacteria. *BMC Complement Altern Med* 2013; **13**: 26.
- [36] Oyagbemi AA, Saba AB, Azeez OI. Capsaicin: a novel chemopreventive molecule and its underlying molecular mechanisms of action. *Indian J Cancer* 2010; **47**: 53-8.
- [37] Bley K, Boorman G, Mohammad B, McKenzie D, Babbar S. A comprehensive review of the carcinogenic and anticarcinogenic potential of capsaicin. *Toxicol Pathol* 2012; **40**: 847-73.